$0.03 EPS Expected for Heska Corp (NASDAQ:HSKA) This Quarter

Share on StockTwits

Equities analysts forecast that Heska Corp (NASDAQ:HSKA) will report earnings per share of $0.03 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Heska’s earnings. The highest EPS estimate is $0.10 and the lowest is ($0.05). Heska reported earnings per share of $0.46 during the same quarter last year, which would suggest a negative year over year growth rate of 93.5%. The company is expected to issue its next quarterly earnings report on Tuesday, February 25th.

According to Zacks, analysts expect that Heska will report full year earnings of $0.05 per share for the current fiscal year, with EPS estimates ranging from ($0.02) to $0.12. For the next year, analysts expect that the firm will report earnings of $0.19 per share, with EPS estimates ranging from $0.03 to $0.34. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Heska.

Heska (NASDAQ:HSKA) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04). The company had revenue of $31.24 million during the quarter, compared to analysts’ expectations of $30.44 million. Heska had a return on equity of 3.17% and a net margin of 3.15%.

Several research firms have recently commented on HSKA. Piper Jaffray Companies began coverage on shares of Heska in a research note on Wednesday, September 18th. They issued a “neutral” rating and a $68.00 target price for the company. ValuEngine downgraded shares of Heska from a “strong-buy” rating to a “buy” rating in a report on Friday, January 3rd. Canaccord Genuity restated a “buy” rating and issued a $105.00 target price (up from $75.00) on shares of Heska in a report on Wednesday, November 6th. Raymond James downgraded shares of Heska from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. They noted that the move was a valuation call. Finally, BidaskClub downgraded shares of Heska from a “strong-buy” rating to a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $85.75.

Hedge funds have recently made changes to their positions in the business. FMR LLC lifted its stake in Heska by 2.0% during the first quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock valued at $38,616,000 after buying an additional 8,870 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Heska by 6.9% in the second quarter. Envestnet Asset Management Inc. now owns 4,794 shares of the medical research company’s stock worth $408,000 after purchasing an additional 309 shares during the period. JPMorgan Chase & Co. increased its position in Heska by 1,229.0% in the second quarter. JPMorgan Chase & Co. now owns 21,876 shares of the medical research company’s stock worth $1,834,000 after purchasing an additional 20,230 shares during the period. Bank of Montreal Can increased its position in Heska by 30.3% in the second quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock worth $183,000 after purchasing an additional 503 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Heska by 6.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 41,417 shares of the medical research company’s stock worth $3,528,000 after buying an additional 2,423 shares during the last quarter. 97.92% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:HSKA traded up $1.41 during trading hours on Thursday, reaching $95.49. 778 shares of the company’s stock were exchanged, compared to its average volume of 61,637. Heska has a 1-year low of $62.47 and a 1-year high of $102.09. The firm has a market capitalization of $733.59 million, a price-to-earnings ratio of 67.26 and a beta of 1.10. The company has a quick ratio of 6.80, a current ratio of 8.52 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $95.16 and a 200 day moving average of $81.72.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Read More: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.